

M. Laurent MEESCHAERT  
28 rue Saint Lazare  
75009 PARIS  
FRANCE

ELI LILLY AND COMPANY  
Mr Donald G. THERASSE  
Vice President  
Global Patient Safety and Bioethics  
Lilly Corporate Center  
INDIANAPOLIS, INDIANA 46286  
USA

Paris, February 5th 2013

Dear Mr Therasse,

I thank you for allowing me to post our correspondence on the website [www.embryo-ethics.com](http://www.embryo-ethics.com).

In your letter of January 29, 2013, you underline the fact that Lilly has not and is currently not conducting research with human embryonic (or fetal) stem cells, nor do you have plans to do so. As you rightly mentioned it, the purpose of my survey is to reflect current practice. Consequently, I am giving my financial advisers the option of investing in Lilly's securities and bonds, whether directly or indirectly. By the way, I transfer your company to the classification "no research on human embryo stem cells".

In your letter, you also state that "consideration of embryonic stem cell research would be quite exceptional, and would require rigorous due diligence to confirm that the research addresses a compelling medical need and the scientific question cannot be answered adequately by an alternative method". Please note that, from my point of view, no good reason will ever legitimate the destruction of human embryos for the end does not justify the means. Therefore, would Lilly conduct research with human embryonic stem cells, even on special case, I would have to reconsider my position and move your company to the classification "research on human embryo stem cells".

I encourage you to continue with research techniques that are fully respectful of the integrity and the dignity of the human embryo.

Sincerely,

  
Laurent MEESCHAERT

cc :

- Dr. John Lechleiter
- M. Dominique Amory (Lilly France – Suresnes)